Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma

被引:103
作者
Lindnér, P
Doubrovsky, A
Kam, PCA
Thompson, JF
机构
[1] Royal Prince Alfred Hosp, Dept Anaesthet, Sydney, NSW, Australia
[2] Royal Prince Alfred Hosp, Sydney Melanoma Unit, Sydney, NSW, Australia
[3] Univ Sydney, Dept Surg, Sydney, NSW 2006, Australia
关键词
hypoxia; isolated limb infusion; melanoma; melphalan; prognostic factors; regional chemotherapy;
D O I
10.1245/aso.2002.9.2.127
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Isolated limb pet-fusion (ILP) with cytotoxic agents is a remark-ably effective but complex technique used to treat locally recurrent and metastatic melanoma confined to a limb. Isolated limb infusion (ILI), essentially a low-flow ILP performed without oxygenation via percutaneous catheters, has been developed as a simpler alternative. Methods: The outcome in 135 patients treated by ILI was reviewed. Results: The overall response rate in the treated limb was 85% (complete response [CR] rate 41%, partial response rate 44%). Median response duration response was 16 months (24 months for patients with CR). Median patient survival was 34 months. In those with a CR, the median survival was 42 months. CR rate and survival time decreased with increasing disease stage. Patients aged >70 years had a better overall response than younger patients. On multivariate analysis, factors associated with an improved outcome were a lower stage of disease, a final limb temperature >37.8degreesC, and a tourniquet time >40 minutes. Conclusions: The frequency and duration of responses after ILI were comparable to those achieved by conventional ILP. The ILI technique is particularly useful for older patients who might not be considered suitable for conventional ILP.
引用
收藏
页码:127 / 136
页数:10
相关论文
共 26 条
[1]  
COX DR, 1972, J R STAT SOC B, V34, P187
[2]  
DIFILIPPO F, 1989, CANCER, V63, P2551
[3]   HYPERTHERMIC PERFUSION WITH CHEMOTHERAPY FOR MELANOMA OF THE EXTREMITIES [J].
GHUSSEN, F ;
KRUGER, I ;
SMALLEY, RV ;
GROTH, W .
WORLD JOURNAL OF SURGERY, 1989, 13 (05) :598-602
[4]   REGIONAL HYPERTHERMIC PERFUSION WITH MELPHALAN AFTER SURGERY FOR RECURRENT MALIGNANT-MELANOMA OF THE EXTREMITIES [J].
HAFSTROM, L ;
RUDENSTAM, CM ;
BLOMQUIST, E ;
INGVAR, C ;
JONSSON, PE ;
LAGERLOF, B ;
LINDHOLM, C ;
RINGBORG, U ;
WESTMAN, G .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (12) :2091-2094
[5]   Clinical management and current research in isolated limb perfusion for sarcoma and melanoma [J].
Hohenberger, P ;
Kettelhack, C .
ONCOLOGY, 1998, 55 (02) :89-102
[6]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[7]   Prophylactic isolated limb perfusion for localized, high-risk limb melanoma:: Results of a multicenter randomized phase III trial [J].
Koops, HS ;
Vaglini, M ;
Suciu, S ;
Kroon, BBR ;
Thompson, JF ;
Göhl, J ;
Eggermont, AMM ;
Di Filippo, F ;
Krementz, ET ;
Ruiter, D ;
Lejeune, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) :2906-2912
[8]   RESULTS OF A DOUBLE PERFUSION SCHEDULE WITH MELPHALAN IN PATIENTS WITH MELANOMA OF THE LOWER-LIMB [J].
KROON, BBR ;
KLAASE, JM ;
VANGEEL, BN ;
EGGERMONT, AMM ;
FRANKLIN, HR ;
VANDONGEN, JA .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (03) :325-328
[9]  
KROON BBR, 1988, EUR J SURG ONCOL, V14, P101
[10]  
KROON BBR, 1992, REG CANCER TREAT, V4, P305